Skip to main content
SkinCited

Lactobacillus rhamnosus لـ Eczema (Atopic Dermatitis)

B الأدلة تدعم ذلك تجربة عشوائية واحدة على الأقل، مع نتائج متسقة في معظمها.

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u0026condition\u003Deczema\u002Datopic\u002Ddermatitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

الخلاصة

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

Key Study Findings

Review
Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
Dose: None مقابل: None Outcome: Diarrhea, colic, allergy, atopic dermatitis التأثير: None None

المجتمع المدروس: Pediatric patients

Randomized Controlled Trial
[Effectiveness and safety of probiotics in children on the basis of clinical trials].
Dose: None مقابل: None Outcome: diarrhea التأثير: None None

المجتمع المدروس: None

Key Statistics

20

الدراسات

3500

المشاركون

Positive

B

التقييم

Referenced Papers

Archivos argentinos de … 2022 23 اقتباسات
Medycyna wieku rozwojowego 2012 1 اقتباسات

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
1-10 billion CFU/day
atopicdermatitis:
10 billion CFU/day L. rhamnosus GG

الحد الأعلى: Not established; generally well-tolerated at doses up to 100 billion CFU/day

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
None -- Positive --
None -- Positive --

أفضل وقت للتناول: Before or with meals; some studies suggest empty stomach

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • Mild gas or bloating (temporary, during initial use)
  • Rare infections in severely immunocompromised individuals

التفاعلات المعروفة

  • Immunosuppressants (theoretical concern — live bacteria)
  • Antibiotics (may reduce probiotic viability — separate by 2+ hours)

الحد الأقصى المسموح به: Not established; generally well-tolerated at doses up to 100 billion CFU/day

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does Lactobacillus rhamnosus help with Eczema (Atopic Dermatitis)?
Based on 20 studies with 3,500 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus may support Eczema (Atopic Dermatitis) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus should I take for Eczema (Atopic Dermatitis)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus?
Reported side effects may include Mild gas or bloating (temporary, during initial use), Rare infections in severely immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus and Eczema (Atopic Dermatitis)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 3,500 total participants. The overall direction of effect is positive.

مكونات أخرى لـ Eczema (Atopic Dermatitis)

Lactobacillus rhamnosus لحالات أخرى

References

  1. [1] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  2. [2] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.